Skin Cancer & Melanoma

Latest News

Phase 1b findings may affirm the therapeutic potential of IMA203 for patients with previously treated metastatic melanoma.
PRAME-Targeted Agent Shows Activity in Pretreated Metastatic Melanoma

October 14th 2024

Phase 1b findings may affirm the therapeutic potential of IMA203 for patients with previously treated metastatic melanoma.

The safety profile of fianlimab/cemiplimab in a phase 1 trial was consistent with prior reports of cemiplimab monotherapy.
Fianlimab Combo Shows Activity in Advanced Melanoma Subtypes

October 14th 2024

Phase 2 data also show responses with atezolizumab switch therapy in a population of patients with BRAF V600–positive melanoma.
Survival Improves With Atezolizumab Switch Therapy in BRAF+ Melanoma

September 17th 2024

Support for the decision follows phase 1 findings evaluating IBI363 in patients with advanced solid tumors presented at the 2024 ESMO Plenary.
IBI363 Monotherapy Gets Fast Track Status for Advanced Melanoma

September 5th 2024

Preliminary results from part 2 of the phase 2 trial evaluating VP-315 in basal cell carcinoma found no dose-limiting toxicities or treatment-related serious adverse events.
Encouraging Tumor Shrinkage Observed in VP-315 for Basal Cell Carcinoma

August 28th 2024

More News